Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study

Enrico Franceschi, Roberta Depenni, Alexandro Paccapelo, Mario Ermani, Marina Faedi, Carmelo Sturiale, Maria Michiara, Franco Servadei, Giacomo Pavesi, Benedetta Urbini, Anna Pisanello, Girolamo Crisi, Michele A. Cavallo, Claudio Dazzi, Claudia Biasini, Federica Bertolini, Claudia Mucciarini, Giuseppe Pasini, Agostino Baruzzi, Alba A. BrandesPerno Study Group The Perno Study Group

Research output: Contribution to journalArticle

Abstract

The role of temozolomide concurrent with and adjuvant to radiotherapy (RT/TMZ) in elderly patients with glioblastoma (GBM) remains unclear. We evaluated the outcome of patients >70 years in the context of the Project of Emilia-Romagna Region in Neuro-Oncology (PERNO), the first Italian prospective observational population-based study in neuro-oncology. For this analysis the criteria for selecting patients enrolled in the PERNO study were: age >70 years; PS 0–3; histologically confirmed GBM; postoperative radiotherapy (RT) after surgery with or without concomitant temozolomide (TMZ) or postsurgical TMZ alone. Between January 2009 and December 2010, 76 GBM elderly patients were identified in the prospective PERNO study. Twenty-three patients did not receive any treatment after surgery, and 53 patients received postsurgical treatments (25 patients received RT alone and 28 patients RT/TMZ). Median survival was 11.1 months (95 % CI 8.8–13.5), adding temozolomide concomitant and adjuvant to radiotherapy it was 11.6 months (95 % CI 8.6–14.6), and 9.3 months (95 % CI 8.1–10.6) in patients treated with RT alone (P = 0.164). However, patients with MGMT methylated treated with RT/TMZ obtained a better survival (17.2 months, 95 % CI 11.5–22.9) (P = 0.042). No difference in terms of survival were observed if patients with MGMT unmethylated tumor received RT alone, or RT/TMZ or, in MGMT methylated tumor, if patients received radiotherapy alone. In elderly patients RT/TMZ represent a widely used approach but it is effective with methylated MGMT tumors only.

Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalJournal of Neuro-Oncology
DOIs
Publication statusAccepted/In press - Mar 4 2016

Fingerprint

temozolomide
Glioblastoma
Radiotherapy
Prospective Studies
Adjuvant Radiotherapy
Survival

Keywords

  • Elderly
  • Glioblastoma
  • MGMT methylation
  • Radiotherapy
  • Temozolomide

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neurology

Cite this

Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study. / Franceschi, Enrico; Depenni, Roberta; Paccapelo, Alexandro; Ermani, Mario; Faedi, Marina; Sturiale, Carmelo; Michiara, Maria; Servadei, Franco; Pavesi, Giacomo; Urbini, Benedetta; Pisanello, Anna; Crisi, Girolamo; Cavallo, Michele A.; Dazzi, Claudio; Biasini, Claudia; Bertolini, Federica; Mucciarini, Claudia; Pasini, Giuseppe; Baruzzi, Agostino; Brandes, Alba A.; The Perno Study Group, Perno Study Group.

In: Journal of Neuro-Oncology, 04.03.2016, p. 1-6.

Research output: Contribution to journalArticle

Franceschi, E, Depenni, R, Paccapelo, A, Ermani, M, Faedi, M, Sturiale, C, Michiara, M, Servadei, F, Pavesi, G, Urbini, B, Pisanello, A, Crisi, G, Cavallo, MA, Dazzi, C, Biasini, C, Bertolini, F, Mucciarini, C, Pasini, G, Baruzzi, A, Brandes, AA & The Perno Study Group, PSG 2016, 'Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study', Journal of Neuro-Oncology, pp. 1-6. https://doi.org/10.1007/s11060-016-2093-1
Franceschi, Enrico ; Depenni, Roberta ; Paccapelo, Alexandro ; Ermani, Mario ; Faedi, Marina ; Sturiale, Carmelo ; Michiara, Maria ; Servadei, Franco ; Pavesi, Giacomo ; Urbini, Benedetta ; Pisanello, Anna ; Crisi, Girolamo ; Cavallo, Michele A. ; Dazzi, Claudio ; Biasini, Claudia ; Bertolini, Federica ; Mucciarini, Claudia ; Pasini, Giuseppe ; Baruzzi, Agostino ; Brandes, Alba A. ; The Perno Study Group, Perno Study Group. / Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study. In: Journal of Neuro-Oncology. 2016 ; pp. 1-6.
@article{9754a70c88984b0495b901768f90faa2,
title = "Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study",
abstract = "The role of temozolomide concurrent with and adjuvant to radiotherapy (RT/TMZ) in elderly patients with glioblastoma (GBM) remains unclear. We evaluated the outcome of patients >70 years in the context of the Project of Emilia-Romagna Region in Neuro-Oncology (PERNO), the first Italian prospective observational population-based study in neuro-oncology. For this analysis the criteria for selecting patients enrolled in the PERNO study were: age >70 years; PS 0–3; histologically confirmed GBM; postoperative radiotherapy (RT) after surgery with or without concomitant temozolomide (TMZ) or postsurgical TMZ alone. Between January 2009 and December 2010, 76 GBM elderly patients were identified in the prospective PERNO study. Twenty-three patients did not receive any treatment after surgery, and 53 patients received postsurgical treatments (25 patients received RT alone and 28 patients RT/TMZ). Median survival was 11.1 months (95 {\%} CI 8.8–13.5), adding temozolomide concomitant and adjuvant to radiotherapy it was 11.6 months (95 {\%} CI 8.6–14.6), and 9.3 months (95 {\%} CI 8.1–10.6) in patients treated with RT alone (P = 0.164). However, patients with MGMT methylated treated with RT/TMZ obtained a better survival (17.2 months, 95 {\%} CI 11.5–22.9) (P = 0.042). No difference in terms of survival were observed if patients with MGMT unmethylated tumor received RT alone, or RT/TMZ or, in MGMT methylated tumor, if patients received radiotherapy alone. In elderly patients RT/TMZ represent a widely used approach but it is effective with methylated MGMT tumors only.",
keywords = "Elderly, Glioblastoma, MGMT methylation, Radiotherapy, Temozolomide",
author = "Enrico Franceschi and Roberta Depenni and Alexandro Paccapelo and Mario Ermani and Marina Faedi and Carmelo Sturiale and Maria Michiara and Franco Servadei and Giacomo Pavesi and Benedetta Urbini and Anna Pisanello and Girolamo Crisi and Cavallo, {Michele A.} and Claudio Dazzi and Claudia Biasini and Federica Bertolini and Claudia Mucciarini and Giuseppe Pasini and Agostino Baruzzi and Brandes, {Alba A.} and {The Perno Study Group}, {Perno Study Group}",
year = "2016",
month = "3",
day = "4",
doi = "10.1007/s11060-016-2093-1",
language = "English",
pages = "1--6",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Springer New York LLC",

}

TY - JOUR

T1 - Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study

AU - Franceschi, Enrico

AU - Depenni, Roberta

AU - Paccapelo, Alexandro

AU - Ermani, Mario

AU - Faedi, Marina

AU - Sturiale, Carmelo

AU - Michiara, Maria

AU - Servadei, Franco

AU - Pavesi, Giacomo

AU - Urbini, Benedetta

AU - Pisanello, Anna

AU - Crisi, Girolamo

AU - Cavallo, Michele A.

AU - Dazzi, Claudio

AU - Biasini, Claudia

AU - Bertolini, Federica

AU - Mucciarini, Claudia

AU - Pasini, Giuseppe

AU - Baruzzi, Agostino

AU - Brandes, Alba A.

AU - The Perno Study Group, Perno Study Group

PY - 2016/3/4

Y1 - 2016/3/4

N2 - The role of temozolomide concurrent with and adjuvant to radiotherapy (RT/TMZ) in elderly patients with glioblastoma (GBM) remains unclear. We evaluated the outcome of patients >70 years in the context of the Project of Emilia-Romagna Region in Neuro-Oncology (PERNO), the first Italian prospective observational population-based study in neuro-oncology. For this analysis the criteria for selecting patients enrolled in the PERNO study were: age >70 years; PS 0–3; histologically confirmed GBM; postoperative radiotherapy (RT) after surgery with or without concomitant temozolomide (TMZ) or postsurgical TMZ alone. Between January 2009 and December 2010, 76 GBM elderly patients were identified in the prospective PERNO study. Twenty-three patients did not receive any treatment after surgery, and 53 patients received postsurgical treatments (25 patients received RT alone and 28 patients RT/TMZ). Median survival was 11.1 months (95 % CI 8.8–13.5), adding temozolomide concomitant and adjuvant to radiotherapy it was 11.6 months (95 % CI 8.6–14.6), and 9.3 months (95 % CI 8.1–10.6) in patients treated with RT alone (P = 0.164). However, patients with MGMT methylated treated with RT/TMZ obtained a better survival (17.2 months, 95 % CI 11.5–22.9) (P = 0.042). No difference in terms of survival were observed if patients with MGMT unmethylated tumor received RT alone, or RT/TMZ or, in MGMT methylated tumor, if patients received radiotherapy alone. In elderly patients RT/TMZ represent a widely used approach but it is effective with methylated MGMT tumors only.

AB - The role of temozolomide concurrent with and adjuvant to radiotherapy (RT/TMZ) in elderly patients with glioblastoma (GBM) remains unclear. We evaluated the outcome of patients >70 years in the context of the Project of Emilia-Romagna Region in Neuro-Oncology (PERNO), the first Italian prospective observational population-based study in neuro-oncology. For this analysis the criteria for selecting patients enrolled in the PERNO study were: age >70 years; PS 0–3; histologically confirmed GBM; postoperative radiotherapy (RT) after surgery with or without concomitant temozolomide (TMZ) or postsurgical TMZ alone. Between January 2009 and December 2010, 76 GBM elderly patients were identified in the prospective PERNO study. Twenty-three patients did not receive any treatment after surgery, and 53 patients received postsurgical treatments (25 patients received RT alone and 28 patients RT/TMZ). Median survival was 11.1 months (95 % CI 8.8–13.5), adding temozolomide concomitant and adjuvant to radiotherapy it was 11.6 months (95 % CI 8.6–14.6), and 9.3 months (95 % CI 8.1–10.6) in patients treated with RT alone (P = 0.164). However, patients with MGMT methylated treated with RT/TMZ obtained a better survival (17.2 months, 95 % CI 11.5–22.9) (P = 0.042). No difference in terms of survival were observed if patients with MGMT unmethylated tumor received RT alone, or RT/TMZ or, in MGMT methylated tumor, if patients received radiotherapy alone. In elderly patients RT/TMZ represent a widely used approach but it is effective with methylated MGMT tumors only.

KW - Elderly

KW - Glioblastoma

KW - MGMT methylation

KW - Radiotherapy

KW - Temozolomide

UR - http://www.scopus.com/inward/record.url?scp=84960094715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960094715&partnerID=8YFLogxK

U2 - 10.1007/s11060-016-2093-1

DO - 10.1007/s11060-016-2093-1

M3 - Article

AN - SCOPUS:84960094715

SP - 1

EP - 6

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

ER -